RNA(RNA)
RNA
Q3 2026 EPS Estimate
$-1.18
Aug 13, 2026 · Reports before open
Revenue Estimate
$666,667
Analyst Sentiment
Wall St. Consensus
Hold15 analysts·Moderate coverage
62
Score
7 Buy (47%)8 Hold (53%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
747%
Hold
853%
Sell
00%
Strong Sell
00%
Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.
Price Target Expectations
Bear
$25.00
+122.2%
Consensus
$25.00
+122.2%
Bull
$25.00
+122.2%
12-Month Target Range15 analysts
$25.00$25.00$25.00
Current $11.25Consensus
Current Price
$11.25
Upside to Consensus
$13.75
Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.
Earnings & Revenue Estimates
Forward Growth Estimates (YoY)
FY2027
Rev-87.65%
EPS—
FY2028
Rev+50.00%
EPS—
FY2029
Rev+40123.39%
EPS—
Raw consensus estimates (low / average / high) from covering analysts.
Annual
| Metric | FY2026E | FY2027E | FY2028E | FY2029E | FY2030E |
|---|---|---|---|---|---|
| Revenue Avg | $22M | $3M | $4M | $1.61B | $19M |
| Low | $9M | $1M | $2M | $910M | $11M |
| High | $50M | $4M | $6M | $2.49B | $29M |
| EBITDA Avg | $-22M | $-3M | $-4M | $-1.61B | $-19M |
| Low | $-50M | $-4M | $-6M | $-2.49B | $-29M |
| High | $-9M | $-1M | $-2M | $-910M | $-11M |
| EBIT Avg | $-22M | $-3M | $-4M | $-1.61B | $-19M |
| Low | $-50M | $-4M | $-6M | $-2.49B | $-29M |
| High | $-9M | $-1M | $-2M | $-910M | $-11M |
| Net Income Avg | $-61M | $-100M | $-110M | $-77M | $-70M |
| Low | $-138M | $-165M | $-116M | $-132M | $-121M |
| High | $-35M | $-42M | $-92M | $-33M | $-31M |
| EPS Avg | $-4.70 | $-5.61 | $-6.08 | $-4.50 | $-4.11 |
| Low | $-8.05 | $-9.62 | $-6.80 | $-7.71 | $-7.05 |
| High | $-2.04 | $-2.44 | $-5.35 | $-1.95 | $-1.79 |
| Analysts (Rev / EPS) | 3 / 1 | 3 / 1 | 2 / 2 | 1 / 1 | 1 / 1 |
Quarterly
| Metric | Q3 2026 | Q4 2026 | Q1 2027 | Q2 2027 | Q3 2027 | Q4 2027 |
|---|---|---|---|---|---|---|
| Revenue Avg | $666,667 | $666,667 | $20M | $20M | $20M | $20M |
| Low | $666,665 | $666,667 | $20M | $20M | $20M | $20M |
| High | $666,668 | $666,667 | $20M | $20M | $20M | $20M |
| EBITDA Avg | $-666,667 | $-666,667 | $-20M | $-20M | $-20M | $-20M |
| Low | $-666,668 | $-666,667 | $-20M | $-20M | $-20M | $-20M |
| High | $-666,665 | $-666,667 | $-20M | $-20M | $-20M | $-20M |
| EBIT Avg | $-666,667 | $-666,667 | $-20M | $-20M | $-20M | $-20M |
| Low | $-666,668 | $-666,667 | $-20M | $-20M | $-20M | $-20M |
| High | $-666,665 | $-666,667 | $-20M | $-20M | $-20M | $-20M |
| Net Income Avg | $-20M | $-24M | $-25M | $-25M | $-26M | $-26M |
| Low | $-20M | $-24M | $-25M | $-25M | $-26M | $-26M |
| High | $-20M | $-24M | $-25M | $-25M | $-26M | $-26M |
| EPS Avg | $-1.18 | $-1.38 | $-1.46 | $-1.46 | $-1.51 | $-1.51 |
| Low | $-1.18 | $-1.38 | $-1.46 | $-1.46 | $-1.51 | $-1.51 |
| High | $-1.18 | $-1.38 | $-1.46 | $-1.46 | $-1.51 | $-1.51 |
| Analysts (Rev / EPS) | 3 / 1 | 2 / 1 | 1 / 1 | 2 / 1 | 2 / 1 | 1 / 1 |